
Prioritization, Costing and Resource Mobilization for NCCPs

Dr. Mary Nyangasi

Technical Officer, Cancer

World Health Organization



Dr. Mary Nyangasi
Technical Officer, Cancer
World Health Organization



Good practices for NCCP planning

- Government stewardship & ownership: for leadership, ownership, accountability, resource allocation
- Alignment with relevant global and regional initiatives
- Aligns with national health strategy , overall govt agenda and other health programs
- Multisectoral and multistakeholder engagement
- Equity, human rights, pt-centred



Government-led process, with stakeholder engagement and participation



PHASE 1 – Planning and preparation

- Establishing a core organizing team
- Developing a costed roadmap
- Confirming and mobilizing resources

PHASE 2 – Conducting the situation analysis

- Review of epidemiology and determinants of TB_a
- TB programme review_b
- Data and evidence consolidation
- Synthesis by stakeholders

PHASE 3 – Formulating goal(s), objectives, interventions and activities

- Formulating goal(s) and objectives
- Identifying priority interventions
- Determining epidemiological (coverage) targets
- Formulating activities and subactivities
- Contingency planning

PHASE 4 – Developing the metrics and activities for monitoring, evaluation and review

- Formulating indicators and targets for activities and subactivities
- Outlining activities for monitoring, evaluation

PHASE 5 – Costing

- Producing cost estimates
- Identifying projected funding and sources

PHASE 6 – Consensus and endorsement, dissemination and resource mobilization

- Consensus and endorsement
- Dissemination and advocacy
- Resource mobilization


9–12 months




Prioritization

- During planning, goals and objectives are identified to define the priority interventions and target setting (**prioritization**). The M&E framework is also defined at this stage.
- The process of making choices between different options to address the most important health needs given scarce resources.
- Should be evidence-based, unbiased, impartial and should be seen as fair by all affected parties
- Priorities reflect a compromise among stakeholders
- Societal values and goals should guide

The Phases of a Program Management Cycle




Universal health coverage and cancer




Ideally we would like to cover everyone with effective cancer services

But we have limited resources.
So how do we proceed?



The 3Ds of decision making




Systematic process, institutionalized with legal basis

Source: WHO 2021a

Priority-setting policy dialogue

Status quo: Lack of prioritization

Domain	Example	Process & Outcome
Cancer control plan	70% NCCPs include breast cancer screening YET.... Feasible & cost-effective in <20%	Political but should be based on: Data → Dialogue → Decision-making
Benefit package (UHC)	<20% of packages include palliative care YET...40+% of packages in LIC cover screening	 <p>Cancer control doesn't need to be expensive...</p> <p>But, it does need to be prioritized</p> <p>Basic package implementable for \$US 5-10 per capita</p>
Treatment standards	20% of nEMLs include bevacizumab but not asparaginase	

Priority-setting policy dialogue

Status quo: Lack of prioritization

Domain

Example


Process &
Outcome

Political but should be based on:
Data → Dialogue → Decision-making

(1) Define interventions

(2) Focus on scale-up

(3) Evaluate system
readiness



(1) Defining priority interventions

Best investment must reach scale & achieve value for money



	Step 1	Step 2	Step 3
Presentation	WHO "Swiss flag"	WHO "Swiss flag"	Can you still "Swiss-flag" it?
Covering	WHO's role in monitoring and treatment	Monitoring/epidemiology WHO's capacity monitoring	Can you still monitor? Can you still treat?
Pathology	WHO's role in diagnosis of infectious diseases Phylogenetic analysis and molecular epidemiology WHO's role in surveillance	WHO's role in diagnosis of infectious diseases Phylogenetic analysis and molecular epidemiology	Can you still diagnose ? Can you still surveil ?
Outgoing	WHO's role in research Coordinated epidemiological surveillance WHO's role in research	Division one of compromised countries WHO's role in research	Expected to research emerging issues and research WHO's role in research
Summary	WHO's role in research Coordinated epidemiological surveillance WHO's role in research	Can you still research ?	WHO's role in research
Outgoing theory	WHO's role in research Coordinated epidemiological surveillance WHO's role in research	Expected to research emerging issues and research WHO's role in research	Expected to research emerging issues and research WHO's role in research
Outgoing	WHO's role in research Coordinated epidemiological surveillance WHO's role in research	Expected to research emerging issues and research WHO's role in research	Expected to research emerging issues and research WHO's role in research

[illegible]

OP1

- Develop **resource-stratified tool kits** to establish and implement comprehensive programmes... **leveraging work of other organizations**

OP2

- Collect, synthesize and disseminate evidence on the **most cost-effective interventions**...and to make an **investment case** for cancer

OP3

- Strengthen the capacity of the Secretariat to support implementation of cost-effective interventions and **country-adapted models...**

1) *Priority interventions defined as buys*

Country Example

WHO, IARC, IAEA prioritization

1st Feasibility assessment, scenarios and priorities

Management Policies		
Cancer guidelines	yes	
Cancer guidelines incl drug-specific protocols	yes	
Cancer guidelines (utilized in >50% facilities)	yes	
Cancer guideline (last updated)	2019	
Cancer guidelines (include referral criteria)	yes	
Breast cancer early detection pgm/guidelines	yes	
Cervical cancer early detection pgm/guidelines	yes	
Colon cancer early detection pgm/guidelines	no	
Childhood cancer early detection pgm/guidelines	no	
Breast cancer defined referral		
Cervical cancer defined referral		
Colon cancer defined referral		
Childhood cancer defined referral	no	
Breast cancer screening pgm	yes	
Breast cancer screening pgm (type)	opportunistic	
Breast cancer screening pgm (method)	clinical breast exam	
Breast cancer screening pgm (coverage)	>50% and <70%	
Breast cancer screening pgm (target age start)		15
Breast cancer screening pgm (target age end)		60
Breast screening test performance (sens)		
Breast screening test performance (sens)		
Cervical cancer screening pgm	yes	
Cervical cancer screening pgm (type)	opportunistic	
Cervical cancer screening pgm (method)	visual inspection	
Cervical cancer screening pgm (coverage)	>50% and <70%	
Cervical cancer screening (STEPS)		
Cervical cancer screening pgm (target age start)		15
Cervical cancer screening pgm (target age end)		60

Goal: ↑coverage by 1% per yr, focusing on women + children

2nd Health system planning & capacity



EQUIPMENT

Pathology
Radiology
Cancer Diagnosis
Prostate Cancer
Diagnosis
Palliative care



CONSUMABLES

Records
Endoscopy
Radiology and Nuclear
Medicine Treatment
Palliative care.




TRAINING

In service training
Quality control programs
Early Diagnosis Policies
Service Organization
Others

Capacity: workforce as bottleneck to reach goal




3rd Generate business model




— **Baseline (no further investment)**
— **Scale-up (1% ↑ coverage / year)**

Investment: ↑\$US 0.30 to save 100 lives per year (50% <60yo)




- Matching tools to country-based stakeholder needs



Use cases

- Matching tools to country-based stakeholder needs




Justifications:


- (1) **<30%** HBP include essential cancer services
- (2) **9%** NCCP are costed
- (3) **<5%** ODA allocated to cancer
- (4) **>70%** cancer programs w/ insufficient HWF


Use cases

- Matching tools to country-based stakeholder needs



WHO-IARC Costing Tool structure






Data inputs

- ✓ **Disease burden**
 - ✓ By cancer, by 5yr age cohort
 - ✓ Stage distribution
 - ✓ **Current outcomes**
 - ✓ Survival by stage by cancer
 - ✓ Treatment delays, abandonment
 - ✓ **Health system capacities**
 - ✓ Workforce by occupation
 - ✓ Technology availability (by facility)
 - ✓ Expenditure on cancer (including meds)
 - ✓ Referral to private sector or globally
 - ✓ MoH capabilities & governance
- **Service coverage** (by cancer) (patients per facility)

SELECTING PACKAGE & SCALE-UP SCENARIOS



OUTPUTS

Health Impact

- Lives saved
- Cases averted
- DALYs / HLYg

Health System Requirements

- Facilities
- Health workforce
- Capital & recurrent costs
- Programmatic costs

Scale-Up

- Costs
- Coverage rates

Total Costs

- Costs
- *Financing approaches*

Sources of funding

Who is providing the financing?



```
graph LR; A((Revenue raising)) --- B[Domestic]; A --- C[External]; A --- D[Innovative];
```

Revenue raising

Domestic

(1) Prefinancing:

(a) **Mandatory** (general govern't expenditure)

(b) **Voluntary** (eg, private insurer, community-based)

(2) Out-of-pocket payment (OOP)

External

(1) Loans for national/international banks

(2) Grants from donors, development assistance

(3) In-kind support (minor)

Innovative


e.g. Innovative financing instruments

Share of health spending


Burden of OOP




Low income




Lower middle income




Upper middle income



High income



Financial burden of cancer to households




Financial catastrophe due to the costs of cancer treatment

- In many countries, families bear cost of cancer care
- Large out-of-pocket spending puts a heavy burden on families, especially poor
- **50-90% risk** of impoverishment due to catastrophic health spending → generational impoverishment.
- **30-80% risk** of abandonment

Development assistance (grants)

Not coming, not enough



In 2019, \$730 million DAH for NCDs

Making cancer care available

Health financing system



How do we spend it? (*economic factors*)

- To promote equitable, resource use?

So, where do we go
from here?



Where does the money come from? (*financial factors*)

- To ensure sufficient and sustainable financing?

Actions that facilitate implementation of national strategic plans

The main actions that facilitate the implementation of NSPs are:


- 1. Supportive supervision**- a facilitative approach that enables mentorship, joint problem solving and communication between the mentee and supervisor
- 2. Monitoring**
- 3. Evaluation**
- 4. Reviews** (quarterly, annual, mid-term of end term)

Guiding principles: *governance, capacity building & accountability*



Strategies for impact

Foundations for success



Threats to impact

	Before plan implementation*	After plan implementation†	p value‡
Absolute change in prevalence of smoking in men, 2000–15§ 24			
All countries (n=59)	-2.1% (4.2)	-1.4% (4.0)	0.17
Tobacco strategy specified (n=53)	-2.0% (4.4)	-1.2% (4.2)	0.07
Tobacco strategy not specified (n=6)	-3.8% (1.4)	-3.3% (1.2)	0.10
Availability of breast cancer screening programme, 2010–15§ 8			
All countries (n=48)	42 (88%)	36 (75%)	0.10
Breast cancer screening strategy specified (n=43)	38 (88%)	34 (79%)	0.70
Breast cancer screening strategy not specified (n=5)	4 (80%)	2 (40%)	0.07
New radiotherapy units acquired per year, 1965–2018§ 25			
All countries (n=60)	1.9 (2.9)	3.7 (4.8)	0.01
Radiotherapy mentioned (n=33)	2.4 (3.7)	4.9 (5.9)	0.01

Effective cancer strategy requires

- ✓ Resources to operationalize
- ✓ MoH focal point
- ✓ Investment in infrastructure & workforce
- ✓ **Robust M&E mechanism with accountability**

A well-structured evidence-based, costed NCCP with clearly defined goals, targets and clear monitoring and evaluation framework is in itself a resource mobilization tool.

Why? Funding gap identified during costing exercise is highlighted during the dissemination exercise and can be used to reach out to funding partners.

Conclusions

Where to go from here

- ✓ **Costing is essential.**

Approach should focus on **process**, not outcome: **ownership is important**

- Priority-setting, stakeholder-led “**dialogues**” foundational to success, founded on “**data**”
- “Decision”: **align timing** with broader policy discussions (eg, national health plans)

- ✓ Priority setting **can be** done by cancer type and intervention type

- ✓ WHO – working with IARC, IAEA, ICCP and others – have tools to support

- **Data-driven** decisions are best, based on **health systems investments**

- ✓ Financing cancer control: requires **multi-dimensional dialogues**

Based on need and financing streams (eg, governmental agencies, development banks)

Must focus on **domestic financing** for sustainability

Investment cases must show the **full social and economic impact of cancer**

Thank you

nyangasim@who.int

S.NO.	Name of technical resource	Link to resources	What year was this resource last updated?
1	Cancer control : knowledge into action : WHO guide for effective programmes ; module 1. Planning	https://www.who.int/publications/i/item/9241546999	2006
2	Cancer control: Prevention	https://www.who.int/publications/i/item/9241547111	2007
3	Cancer control: Early detection	https://www.who.int/publications/i/item/9789241547338	2006
4	Cancer control: Diagnosis and treatment	https://www.who.int/publications/i/item/9241547406	2011
5	Cancer control: Palliative Care	https://www.who.int/publications/i/item/9241547345	2014
6	Cancer control: Policy and advocacy	https://www.who.int/publications/i/item/9241547529	2008
7	Global breast cancer initiative implementation framework: assessing, strengthening and scaling up of services for the early detection and management of breast cancer: executive summary	https://www.who.int/publications/i/item/9789240067134	2023
8	Global breast cancer initiative implementation framework: assessing, strengthening and scaling up of services for the early detection and management of breast cancer	https://www.who.int/publications/i/item/9789240065987	2023
9	National Cancer Control Programmes	https://www.who.int/publications/i/item/national-cancer-control-programmes	2002
10	WHO Guide to cancer early diagnosis	https://www.who.int/publications/i/item/9789241511940	2017
11	Guide for establishing a pathology laboratory in the context of cancer control	https://www.who.int/publications/i/item/guide-for-establishing-a-pathology-laboratory-in-the-context-of-cancer-control	2020
13	Roadmap towards a National Cancer Control Programme	https://www.iaea.org/sites/default/files/19/10/milestones-document-2019.pdf	2019
14	National cancer control programmes core capacity self-assessment tool	https://www.who.int/publications/i/item/national-cancer-control-programmes-core-capacity-self-assessment-tool	2011